Chen Chiu-Ling, Wu Jaw-Ching, Chen Guan-Yu, Yuan Pei-Hsiang, Tseng Yen-Wen, Li Kuei-Chang, Hwang Shiaw-Min, Hu Yu-Chen
Department of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan.
Department of Medical Research and Education, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
Mol Ther. 2015 Jan;23(1):79-88. doi: 10.1038/mt.2014.126. Epub 2014 Jul 15.
MicroRNA 122 (miR-122) is a tumor suppressor for hepatocellular carcinoma (HCC) but is lowly expressed in HCC cells. MiR-151 is aberrantly overexpressed in HCC cells and promotes HCC metastasis yet its roles on HCC tumorigenicity are unknown. To combat HCC tumorigenicity/metastasis, we developed Sleeping Beauty (SB)-based hybrid baculovirus (BV) vectors that expressed (i) miR-122 precursors (pre-miR-122), (ii) miR-151 sponges, or (iii) pre-miR-122 and miR-151 sponges. Transduction of aggressive HCC cells (Mahlavu) with the pre-miR-122-expressing BV tremendously enhanced miR-122 levels for >6 weeks, suppressed the levels of downstream effectors (e.g., ADAM10 and Bcl-w), proliferation, anchorage-independent growth, motility and migration/invasion in vitro. Intratumoral injection of the pre-miR-122-expressing BV attenuated the HCC growth/metastasis. The miR-151 sponges-expressing BV diminished the miR-151 levels for 6 weeks, enhanced RhoGDIA expression, suppressed RhoGTPases, as well as motility and migration/invasion of Mahlavu cells. Intratumoral injection of the miR-151 sponge-expressing BV impeded not only HCC metastasis but also cell proliferation, MMP expression and tumor growth in vivo. The BV co-expressing pre-miR-122 and miR-151 sponges also simultaneously enhanced miR-122 expression and inhibited miR-151, and conferred antitumor/anti-metastasis effects albeit lack of synergism. These data implicate the potentials of the SB-based hybrid BV for persistently modulating miRNA and suppressing HCC tumorigenicity/metastasis.
微小RNA 122(miR - 122)是肝细胞癌(HCC)的肿瘤抑制因子,但在肝癌细胞中低表达。miR - 151在肝癌细胞中异常高表达并促进肝癌转移,但其在肝癌致瘤性方面的作用尚不清楚。为对抗肝癌的致瘤性/转移性,我们构建了基于睡美人(SB)的杂交杆状病毒(BV)载体,其可表达(i)miR - 122前体(pre - miR - 122),(ii)miR - 151海绵体,或(iii)pre - miR - 122和miR - 151海绵体。用表达pre - miR - 122的BV转导侵袭性肝癌细胞(Mahlavu),可使miR - 122水平在6周以上显著升高,抑制下游效应分子(如ADAM10和Bcl - w)水平、增殖、非锚定依赖性生长、体外运动性以及迁移/侵袭。瘤内注射表达pre - miR - 122的BV可减弱肝癌的生长/转移。表达miR - 151海绵体的BV可使miR - 151水平在6周内降低,增强RhoGDIA表达,抑制RhoGTPases以及Mahlavu细胞的运动性和迁移/侵袭。瘤内注射表达miR - 151海绵体的BV不仅可阻碍肝癌转移,还可抑制体内细胞增殖、MMP表达和肿瘤生长。共表达pre - miR - 122和miR - 151海绵体的BV同时增强了miR - 122表达并抑制了miR - 151,虽无协同作用,但仍具有抗肿瘤/抗转移作用。这些数据表明基于SB的杂交BV在持续调节miRNA和抑制肝癌致瘤性/转移性方面具有潜力。